Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endostatin + gemcitabine + nedaplatin + paclitaxel + pirarubicin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
This is a five-drug combination therapy consisting of endostatin (an angiogenesis inhibitor), gemcitabine (a nucleoside analog), nedaplatin (a platinum-based chemotherapeutic), paclitaxel (a taxane), and pirarubicin (an anthracycline). While the specific combination is not well-documented in the provided search results, components of this regimen have shown efficacy in various cancer treatments. Endostatin works by inhibiting angiogenesis and vascular endothelial cell proliferation, while the chemotherapeutic agents target rapidly dividing cancer cells through different mechanisms.
02
Targets
RNR (Ribonucleotide reductase)TOP2A (DNA topoisomerase II)DNA polymerase familyVEGFR3 (Vascular endothelial growth factor receptor 3)αVβ3 (Integrin αVβ3)ITGA5:ITGB1 (Integrin α5β1)DNATUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on endostatin + gemcitabine + nedaplatin + paclitaxel + pirarubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endostatin + gemcitabine + nedaplatin + paclitaxel + pirarubicin.